Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Journal of Clinical Oncology, Vol 23, No 32 (November 10), 2005: pp. 8165-8169
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.03.3134

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klotz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klotz, L.

REVIEW ARTICLE

Active Surveillance for Prostate Cancer: For Whom?

Laurence Klotz

From the University of Toronto, Division of Urology, Sunnybrook & Women's College Health Sciences Centre, Toronto, Ontario, Canada

Address reprint requests to Laurence Klotz, University of Toronto Chief, Division of Urology, Sunnybrook & Women's College Health Sciences Centre, 2075 Bayview Avenue # MG 408, Toronto, Ontario M4N 3M5 Canada; e-mail: laurence.klotz{at}sw.ca.

Prostate-specific antigen (PSA) –based prostate cancer screening results in the diagnosis of prostate cancer in many men who are not destined to have clinical progression during their lifetime. Good-risk prostate cancer, defined as a Gleason score of 6 or less, PSA < 10, and T1c to T2a, now constitutes 50% of newly diagnosed prostate cancer. In most of these patients, the disease is indolent and slow growing. The challenge is to identify those patients who are unlikely to experience significant progression while offering radical therapy to those who are at risk. The approach to favorable-risk prostate cancer described in this article uses estimation of PSA doubling time (PSA DT) to stratify patients according to the risk of progression. Patients who select this approach are managed initially with active surveillance. Those who have a PSA DT of 3 years or less (based on a minimum of three determinations over 6 months) are offered radical intervention. The remainder are closely monitored with serial PSA and periodic prostate rebiopsies (at 2, 5, and 10 years). In this series of 299 patients, the median DT was 7 years. Forty-two percent had a PSA DT > 10 years, and 20% had a PSA DT > 100 years. The majority of patients on this study remain under surveillance. The approach of active surveillance with selective delayed intervention based on PSA DT represents a practical compromise between radical therapy for all (which results in overtreatment for patients with indolent disease) and watchful waiting with palliative therapy only (which results in undertreatment for those with aggressive disease).

Author's disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
NEJMHome page
M. J. Barry, D. S. Kaufman, and C.-L. Wu
Case 15-2008 -- A 55-Year-Old Man with an Elevated Prostate-Specific Antigen Level and Early-Stage Prostate Cancer
N. Engl. J. Med., May 15, 2008; 358(20): 2161 - 2168.
[Full Text] [PDF]


Home page
NEJMHome page
P. C. Walsh, T. L. DeWeese, and M. A. Eisenberger
Localized Prostate Cancer
N. Engl. J. Med., December 27, 2007; 357(26): 2696 - 2705.
[Full Text] [PDF]


Home page
BMJHome page
J A. Lane, J. Howson, J. L Donovan, J. R Goepel, D. J Dedman, L. Down, E. L Turner, D. E Neal, and F. C Hamdy
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial
BMJ, December 1, 2007; 335(7630): 1139 - 1139.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
K. Fizazi
The role of Src in prostate cancer
Ann. Onc., November 1, 2007; 18(11): 1765 - 1773.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A. B Rajput, M. A Miller, A. De Luca, N. Boyd, S. Leung, A. Hurtado-Coll, L. Fazli, E. C Jones, J. B Palmer, M. E Gleave, et al.
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
J. Clin. Pathol., November 1, 2007; 60(11): 1238 - 1243.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. S. Kaufman, W. S. McDougal, A. L. Zietman, and R. H. Young
Case 18-2007 -- A 54-Year-Old Man with Early-Stage Prostate Cancer
N. Engl. J. Med., June 14, 2007; 356(24): 2515 - 2520.
[Full Text] [PDF]


Home page
American Journal of Men's HealthHome page
D. E. Bailey Jr and M. Wallace
Critical Review: Is Watchful Waiting a Viable Management Option for Older Men With Prostate Cancer?
American Journal of Men's Health, March 1, 2007; 1(1): 18 - 28.
[Abstract] [PDF]


Home page
JAMAHome page
M. S. Litwin and D. C. Miller
Treating Older Men With Prostate Cancer: Survival (or Selection) of the Fittest?
JAMA, December 13, 2006; 296(22): 2733 - 2734.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States.
J Natl Cancer Inst, August 16, 2006; 98(16): 1134 - 1141.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. J. Small and E. A. Klein
Challenges and Future Directions in the Prevention and Management of Prostate Cancer
J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online